Kevin K. Manocha
Research Subjects
Research Interests
Kevin K. Manocha has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Bradley Peltzer
Department of Medicine Division of Cardiology Weill Cornell Medicine – New York Presbyterian Hospital New York NY
2 shared publicationsBruce B. Lerman
Department of Medicine Division of Cardiology Weill Cornell Medicine – New York Presbyterian Hospital New York NY
2 shared publicationsJared Kirzner
Department of Medicine Division of Cardiology Weill Cornell Medicine – New York Presbyterian Hospital New York NY
2 shared publications- Jim W. Cheung
Weill Cornell Medicine, New York, New York, USA
2 shared publications Monika M. Safford
Division of General Internal Medicine Department of Medicine Weill Cornell Medicine – New York Presbyterian Hospital New York NY
2 shared publications- Parag Goyal
Program for the Care and Study of the Aging Heart, Department of Medicine, Weill Cornell Medicine, New York, New York, USA
2 shared publications
Latest Publications
- Open Access
- 16 March 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (6) , e018477
Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized With COVID‐19: Derivation and Validation of the HA 2 T 2 COVID‐19 Mortality Risk Score
Background: The independent prognostic value of troponin and other biomarker elevation among patients with coronavirus disease 2019 (COVID‐19) are unclear. We sought to characterize biomarker levels in patients hospitalized with COVID‐19 and develop and validate a mortality risk score. Methods and Results: An observational cohort study of 1053 patients with COVID‐19 was conducted. Patients with all of the following biomarkers measured—troponin‐I, B‐type natriuretic peptide, C‐reactive protein, ferritin, and d ‐dimer (n=446) —were identified. Maximum levels for each biomarker were recorded. The primary end point was 30‐day in‐hospital mortality. Multivariable logistic regression was used to construct a mortality risk score. Validation of the risk score was performed using an independent patient cohort (n=440). Mean age of patients was 65.0±15.2 years and 65.3% were men. Overall, 444 (99.6%) had elevation of any biomarker. Among tested biomarkers, troponin‐I ≥0.34 ng/mL was the only independent predictor of 30‐day mortality (adjusted odds ratio, 4.38; P 2 T 2 ) ≥3 had a 30‐day mortality of 43.7% while those with a score 2 T 2 score was 0.834 for the derivation cohort and 0.784 for the validation cohort. Conclusions: Elevated troponin and other biomarker levels are commonly seen in patients hospitalized with COVID‐19. High troponin levels are a potent predictor of 30‐day in‐hospital mortality. A simple risk score can stratify patients at risk for COVID‐19–associated mortality.
- 16 March 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (6) , e018477
Open AccessTroponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized With COVID‐19: Derivation and Validation of the HA 2 T 2 COVID‐19 Mortality Risk Score
Background: The independent prognostic value of troponin and other biomarker elevation among patients with coronavirus disease 2019 (COVID‐19) are unclear. We sought to characterize biomarker levels in patients hospitalized with COVID‐19 and develop and validate a mortality risk score. Methods and Results: An observational cohort study of 1053 patients with COVID‐19 was conducted. Patients with all of the following biomarkers measured—troponin‐I, B‐type natriuretic peptide, C‐reactive protein, ferritin, and d ‐dimer (n=446) —were identified. Maximum levels for each biomarker were recorded. The primary end point was 30‐day in‐hospital mortality. Multivariable logistic regression was used to construct a mortality risk score. Validation of the risk score was performed using an independent patient cohort (n=440). Mean age of patients was 65.0±15.2 years and 65.3% were men. Overall, 444 (99.6%) had elevation of any biomarker. Among tested biomarkers, troponin‐I ≥0.34 ng/mL was the only independent predictor of 30‐day mortality (adjusted odds ratio, 4.38; P 2 T 2 ) ≥3 had a 30‐day mortality of 43.7% while those with a score 2 T 2 score was 0.834 for the derivation cohort and 0.784 for the validation cohort. Conclusions: Elevated troponin and other biomarker levels are commonly seen in patients hospitalized with COVID‐19. High troponin levels are a potent predictor of 30‐day in‐hospital mortality. A simple risk score can stratify patients at risk for COVID‐19–associated mortality.
- 1 October 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (10) , 1229-1232
Arrhythmic Complications of Patients Hospitalized With COVID-19
- 1 October 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (10) , 1229-1232
Arrhythmic Complications of Patients Hospitalized With COVID-19